All 10 participants in US FDA EAP have commenced treatment
Filed with ASX · · 4 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigm reports Positive Pre-IND meeting with US FDA
- Paradigm - first patient dosed in USA under FDA approved EAP
- Paradigm presents MPS VI poster at WORLD Symposium
- Cleansing Notice and Appendix 3B
- Paradigm End of Calendar Year Update
Later from Paradigm Biopharmaceuticals
- Voluntary Suspension
- Paradigm Latest Corporate Presentation
- Paradigm receives clarity on US regulatory pathway
- Paradigm Reports Very Encouraging Real World Data
- Paradigm completes $35m raising
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals